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July 17, 2014 marks the date of the brutal and unforgivable 
shooting down of Malaysian Airlines flight MH17 over the 
Ukraine, resulting in the death of all its passengers, includ-
ing my longstanding friends and colleagues Joep Lange and 
Jacqueline van Tongeren. They were on their way to attend 
the 20th International Aids Conference, held this year in 
Melbourne, Australia. I myself had already arrived in Mel-
bourne when I heard the devastating news. I was instantly 
struck by an uncontrollable grief and outrage, and the feel-
ing of having lost part of myself. Joep and I were the same 
age: our birthdays are only one day apart, we had gone to 
medical school together, and since 1981 our careers had 
evolved in parallel around HIV. Our private lives were also 
very much intertwined, and Joep had been the knowing 
matchmaker who introduced me to my future spouse and 
mother of five of my six children. 
Jacqueline was also a close friend and colleague who 
first came to work at the Amsterdam Academic Medical 
Center in the late ‘80s’ as head nurse of our Aids-unit and 
subsequently became the coordinating research nurse of the 
National AIDS Therapy Evaluation Center, established in 
1990 as the Dutch HIV trial center, and headed by Joep. She 
was a pillar of support throughout the intervening years for 
everyone at the Center and especially for Joep, and she was 
one of the most caring and loving people I have been privi-
leged to know. 
In the aftermath of this tragic event, Joep has often been 
described as a “giant of HIV/AIDS research”, contributing 
greatly to the well-being of people living with HIV (PLWH).  
Joep MA Lange 
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As the chair of the Dutch association of people living with 
HIV remarked while in Melbourne, PLWH were always 
very much at the centre of everything Joep undertook pro-
fessionally. Not only was he a gifted and caring physician, 
and an innovative and creative entrepreneurial researcher; 
he was also a tireless advocate for access to quality HIV 
care and treatment for all of those in need, be it in the Neth-
erlands or anywhere else in the world. To accomplish what 
Joep believed was the right thing to do, he had no hesitation 
in being politically incorrect and letting his voice be heard 
above the clamour of more traditional views. 
Joep’s contributions to HIV science and the well-being 
of PLWH are too numerous to mention in one article. Very 
early on during his scientific career, as part of his Ph.D. 
thesis he demonstrated that individuals with higher levels of 
the HIV protein p24 were more likely to experience more  
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rapid HIV disease progression, while long-term survivors 
had reduced p24 antigen in their blood. This discovery 
supported the concept of the use of antiretroviral therapy to 
reduce p24 antigen already during clinically asymptomatic 
infection and thereby prevent the onset of AIDS [1]. The 
p24 antigen test was later replaced by the more sensitive 
and accurate tests for measuring HIV RNA which remains 
the hallmark for assessing the success of treatment. Among 
the later favorite scientific achievements Joep himself listed 
on his Curriculum Vitae are being the originator and 
co-principal investigator of several pivotal trials on an-
tiretroviral therapy (INCAS [2], 2NN [3]) and on the pre-
vention of mother to child transmission of HIV (PETRA [4], 
SIMBA). Joep was also instrumental in establishing the 
ATHENA observational cohort in the Netherlands; was 
among the first to attempt to eradicate HIV from its tissue 
reservoirs [5]; and suggested the use of antiretrovirals for 
pre-exposure prophylaxis (PrEP) at a time when these con-
cepts were considered beyond the reach of accepted treat-
ment strategies.  
Joep played a leading role in increasing access to HIV 
treatment and the provision of quality health care in re-
source-limited settings. In 1996, together with David 
Cooper and Praphan Phanuphak, he co-founded and 
co-directed the HIV Netherlands-Australia-Thailand re-
search collaboration (HIV-NAT; www.hivnat.org). In 2000, 
he established the Pharmaccess Foundation (www.   
pharmaccess. org), aimed at initiating HIV treatment pro-
grams in sub-Saharan Africa: subsequent spin-offs, each 
designed to strengthen health systems in sub-Saharan Africa 
by financially viable and sustainable means, have included 
the Health Insurance Fund (www.hifund.org), the Medical 
Credit Fund (www.medicalcreditfund.org), SafeCare (www. 
safe-care.org), and the Investment Fund for Health Care in 
Africa (www.ifhafund.com).  
Joep understood the importance of disseminating 
knowledge and he travelled the world frequently for this 
purpose. In 1995, he established Antiviral Therapy together 
with Doug Richman and Stephen Cameron, and the first 
issue went to print in 1996. In 2003, together with Fransje 
van der Waals, Joep established the Health(e)Foundation 
(www.healthefoundation.eu) which through computerised 
and face-to-face means provides educational material to 
health care providers in resource-limited settings around the 
globe on HIV and other diseases relevant to their region. In 
2007 the annual INTEREST workshop became a focus of 
his attention which he shaped into becoming one of the 
premier scientific HIV conferences in the sub-Saharan Af-
rican region. He has mentored more than 40 Ph.D. students, 
latterly in his role of Professor of Global Health at the Aca-
demic Medical Centre and Executive Scientific Director of 
the Amsterdam Institute for Global Health and Develop-
ment (www.aighd.org). Many of these students have them-
selves moved on to leading academic positions and are con-
tributing their own efforts to the fight against HIV. 
In spite of his many achievements Joep remained a very 
modest person, and was often even shy. He was a man of 
culture, with a broad interest and fondness for both the vis-
ual and performing arts. He read widely, with a great love 
of modern literature as well as for the latest scientific re-
search and read whenever and wherever he could. Many 
years ago the first Netherlands astronaut approached him 
with the idea that putting people into a state of weightless-
ness might improve immune function and could potentially 
be of benefit for treating HIV. Joep volunteered to be the 
human guinea pig for a first experiment. As he entered the 
machine which would spin him into being weightless, he 
took with him a number of copies of New England Journal 
of Medicine and Lancet in order to make best use of his 
time… 
The HIV and global health community will greatly miss 
these two remarkable people and their contributions to HIV 
research and care. And more than ever, their pointless 
deaths remind us that much of what Joep and Jaqueline both 
strived for was an end to intolerance and prejudice. In the 
words of Mr. Laurindo Garcia at the recent IAC in Mel-
bourne, what the world needs is a “vaccine against intoler-
ance”. 
Joep was a loving father to his four daughters Anna, Ma-
ria, Martha, Ottla; and to his son Max; and the grandfather 
of his first grandchild Angus. First and foremost our hearts 
go out to them. 
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